ArticleTherapeutic advances in urology2010
Androgen receptor molecular biology and potential targets in prostate cancer.
Article in Therapeutic advances in urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Relevance of the 21-gene expression assay in male breast cancer: A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2022Pooled it
- Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2013Trial
- Primate-specific melanoma antigen-A11 regulates isoform-specific human progesterone receptor-B transactivation.The Journal of biological chemistry · 2012Trial
- Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer.SLAS discovery : advancing life sciences R & D · 2023Article
- Molecular Modeling Studies of Natural Inhibitors of Androgen Signaling in Prostate Cancer.Cancer informatics · 2022Article
- Pathogenicity of the MAGE family.Oncology letters · 2021Review
- MAGE-A11 Expression Predicts Patient Prognosis in Head and Neck Squamous Cell Carcinoma.Cancer management and research · 2020Article
- Methylation Profile of X-Chromosome-Related Genes in Male Breast Cancer.Frontiers in oncology · 2020Article
- Epigenetic regulation of MAGE family in human cancer progression-DNA methylation, histone modification, and non-coding RNAs.Clinical epigenetics · 2018Review
- Evolution of Melanoma Antigen-A11 (MAGEA11) During Primate Phylogeny.Journal of molecular evolution · 2018Article
- A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases.Journal of molecular biology · 2017Review
- Melanoma antigen-A11 regulates substrate-specificity of Skp2-mediated protein degradation.Molecular and cellular endocrinology · 2017Article
- Contrary melanoma-associated antigen-A expression at the tumor front and center: A comparative analysis of stage I and IV head and neck squamous cell carcinoma.Oncology letters · 2016Article
- Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor.The Journal of biological chemistry · 2015Article
- MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4.PloS one · 2015Article
- Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance.Asian journal of urology · 2014Review
- Correlation of MAGE-A tumor antigens and the efficacy of various chemotherapeutic agents in head and neck carcinoma cells.Clinical oral investigations · 2014Article
- Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins.The Journal of biological chemistry · 2013Article
- Melanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers.The Journal of biological chemistry · 2013Article
- A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.The Journal of biological chemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The androgen receptor (AR) is a key transcriptional regulator and therapeutic target in prostate cancer. During androgen deprivation therapy to treat metastatic prostate cancer, surviving cells acquire increased AR signaling through a variety of mechanisms, one of which is enhanced interactions with AR coactivators. One recently identified AR-specific coregulator expressed only in human and nonhuman primates is the melanoma antigen gene protein-A11 (MAGE-11). MAGE-11 increases AR transcriptional activity through direct interactions with AR and other coactivators, and its levels increase during prostate cancer progression to castration-recurrent growth. The MAGE-11 gene is located at Xq28 on the human X chromosome as part of an X-linked MAGE gene family of cancer-testis antigens. MAGE-11 stabilizes AR when androgen levels are low, and functions in a transcriptional hub to promote AR-mediated gene activation. The evolutionary development and organization of the MAGE-11 gene within the cancer-testis antigen family suggests that MAGE-11 provides a gain-of-function to AR among primates in both normal physiology and cancer, and may serve as a therapeutic target in the treatment of advanced prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.